Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Buys 199,072 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 199,072 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were acquired at an average price of $1.53 per share, with a total value of $304,580.16. Following the transaction, the chief executive officer now owns 211,911,477 shares in the company, valued at approximately $324,224,559.81. The trade was a 0.09 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, November 22nd, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.59 per share, with a total value of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.62 per share, for a total transaction of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost purchased 280,183 shares of OPKO Health stock. The shares were acquired at an average price of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Trading Down 2.5 %

NASDAQ:OPK opened at $1.54 on Friday. The firm has a market capitalization of $1.05 billion, a P/E ratio of -8.11 and a beta of 1.65. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health, Inc. has a one year low of $0.85 and a one year high of $1.75. The company’s 50-day simple moving average is $1.51 and its 200 day simple moving average is $1.45.

Hedge Funds Weigh In On OPKO Health

Several large investors have recently made changes to their positions in OPK. Lazard Asset Management LLC bought a new position in OPKO Health during the 1st quarter valued at approximately $258,000. Price T Rowe Associates Inc. MD grew its stake in shares of OPKO Health by 4.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company’s stock worth $536,000 after acquiring an additional 17,671 shares during the last quarter. Tidal Investments LLC bought a new position in shares of OPKO Health during the first quarter valued at $239,000. Comerica Bank raised its position in shares of OPKO Health by 125.0% in the 1st quarter. Comerica Bank now owns 90,000 shares of the biotechnology company’s stock worth $108,000 after purchasing an additional 50,000 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in OPKO Health in the 1st quarter worth about $26,000. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on OPK. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research note on Thursday, September 26th. Barrington Research reiterated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a report on Friday, November 8th. Finally, Piper Sandler restated an “overweight” rating and set a $3.00 target price on shares of OPKO Health in a report on Tuesday, September 17th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.